Hydrocodone
Hydrocodone is a semi-synthetic prescription opioid for moderate-to-severe pain, most familiar in acetaminophen combinations such as Vicodin and Norco, and a Schedule II controlled substance in the US. Like all opioids its defining danger is respiratory depression — magnified by alcohol or benzodiazepines, by lost tolerance after a break, and by fentanyl-contaminated counterfeit pills in the illicit supply.
Overview
Hydrocodone is a semi-synthetic opioid derived from codeine, used medically for moderate-to-severe pain and, in some formulations, to suppress cough. It is most familiar in combination products that pair it with acetaminophen, sold under brand names such as Vicodin and Norco, and in extended-release single-ingredient formulations. As a prescription opioid it is effective for pain but carries the addiction, overdose and dependence risks common to the opioid class, and it has been a significant contributor to the US opioid epidemic.
Source: DEA; MedlinePlus; peer-reviewed literature (NIH/PMC)
Chemistry & mechanism of action
Hydrocodone is an agonist at mu-opioid receptors in the brain, spinal cord and elsewhere. Activating these receptors reduces the perception of pain and can produce euphoria and drowsiness, but it also suppresses the brainstem centers that drive breathing. This respiratory-depressant effect is the mechanism behind fatal opioid overdose. Repeated activation of opioid receptors leads to tolerance, needing more for the same effect, and to physical dependence, so that stopping produces withdrawal.
Source: MedlinePlus; peer-reviewed literature (NIH/PMC)
Effects
Effects include pain relief, relaxation, drowsiness and for some a sense of euphoria, along with common opioid side effects such as constipation, nausea, itching and pupil constriction. Higher exposures cause pronounced sedation, slowed and shallow breathing, confusion and loss of consciousness. Combination products carry an added danger: the acetaminophen they contain can cause severe, potentially fatal liver injury if intake is high, a risk that is easy to overlook.
Source: MedlinePlus; DEA
Risks & harms
The defining acute danger of hydrocodone, like all opioids, is respiratory depression: breathing slows and can stop, which is how opioid overdoses kill. This risk rises sharply when hydrocodone is combined with other central nervous system depressants such as alcohol, benzodiazepines or other sedatives, because their effects on breathing stack; opioid-plus-depressant combinations are among the deadliest. Tolerance and physical dependence develop with regular use, and a period of abstinence after detox, incarceration or a break sharply lowers tolerance, so a previously routine amount can become fatal. Opioid withdrawal is intensely unpleasant but not usually life-threatening on its own. A critical contamination hazard applies to any opioid obtained outside a pharmacy: the illicit pill supply is widely adulterated with illicitly manufactured fentanyl, and counterfeit tablets pressed to look like genuine hydrocodone or other pharmaceuticals have caused many deaths in people who did not know they were taking fentanyl. Naloxone, sold as Narcan, can reverse an opioid overdose and is increasingly available without a prescription; because fentanyl is so potent, more than one dose may be needed. If someone is unresponsive or breathing slowly, call 911 and give naloxone if available. This page has not yet been medically reviewed.
Source: DEA; SAMHSA; MedlinePlus; peer-reviewed literature (NIH/PMC)
Legal status (US)
In the United States, hydrocodone is a Schedule II controlled substance. Single-ingredient hydrocodone has long been Schedule II, and in 2014 the DEA moved hydrocodone combination products, such as those with acetaminophen, from Schedule III to Schedule II, tightening prescribing rules. Schedule II denotes an accepted medical use alongside a high potential for abuse and severe dependence; prescriptions face strict limits, including on refills. This classification applies nationwide, and state laws add further requirements. Follow a prescriber's directions and local law; consult DEA and FDA resources for specifics. This page has not yet been medically reviewed.
Source: DEA; US federal law; FDA
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling, because penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authority and your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulate in the destination immediately, not the destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass, most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating, move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst, but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing, long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
With opioids, slowed or stopped breathing is the emergency, if available, give naloxone and call 911 immediately; it can be given while you wait for help.
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft, not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown, pending review”Identity
- PubChem CID
- 5284569PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- (4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-onePubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C18H21NO3PubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)CC4PubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- LLPOLZWFYMWNKH-CMKMFDCUSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- vicodin, norco, Dihydrocodeinone, Hydrocodon, Hydrocone, Hydroconum, Bekadid, Multacodin, (-)-Dihydrocodeinone, hidrocodona, Idrocodone, DICOPubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- HUMAN PRESCRIPTION DRUGopenFDA drug label ↗ · retrieved 2026-06-18
- Shape
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Color
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Imprint
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Score
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- Unknown, pending review
Effects, risks & interactions
- Effects
- Hydrocodone is a semi-synthetic opioid and, in the United States, one of the most commonly prescribed — often inside combination pain and cough products, and also available as a single-ingredient extended-release formulation. Acting on opioid receptors, it produces opioid pain relief along with sedation, relaxation and euphoria. As with the class, the strength of these effects tracks the dose and the formulation.NIDA Opioids + PubChem CID 5284569 ↗ · retrieved 2026-06-18
- Risks
- Hydrocodone can cause fatal respiratory depression in overdose, a danger heightened by higher doses, by a lack of tolerance, by tampering with extended-release forms, and above all by combining it with alcohol or other depressants. A hazard specific to its combination products is the other ingredient: formulations that pair hydrocodone with acetaminophen carry a real risk of liver injury if the product is taken in excess to obtain more opioid effect. Constipation, nausea, tolerance and dependence are typical. Naloxone can reverse an opioid overdose if it is used without delay.NIDA Opioids + PubChem CID 5284569 ↗ · retrieved 2026-06-18
- Interactions
- For hydrocodone the label leads with alcohol and sedatives: mixed with benzodiazepines or other CNS depressants it can cause overwhelming sedation and life-threatening slowing of the breath, ending in coma or death. Its metabolism through CYP3A4 and CYP2D6 makes it sensitive to enzyme inhibitors (which push levels up) and inducers (which pull effect down or bring on withdrawal). Serotonergic agents, monoamine-oxidase inhibitors and agonist/antagonist opioids are flagged as further hazards.DailyMed Hydrocodone Bitartrate §7 Drug Interactions ↗ · retrieved 2026-06-18
Pill catalog
Rx/OTC variants · openFDA + DailyMed (public domain) · draft, pending reviewThis drug comes in 229different versions. Make sure you’re looking at the right one, use the search above to find your exact pill by imprint, color, or shape.
Showing 24 of 229 variants
- Strength
- ACETAMINOPHEN 325 mg/1; HYDROCODONE BITARTRATE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 63629-2300 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; HYDROCODONE BITARTRATE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 63629-8885 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; HYDROCODONE BITARTRATE 7.5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 63629-2297 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; HYDROCODONE BITARTRATE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 63629-8886 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; HYDROCODONE BITARTRATE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 63629-2298 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; HYDROCODONE BITARTRATE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 63629-2299 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; HYDROCODONE BITARTRATE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 71335-2585 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; HYDROCODONE BITARTRATE 7.5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 63629-1180 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; HYDROCODONE BITARTRATE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 72162-1279 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; HYDROCODONE BITARTRATE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 63629-1177 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; HYDROCODONE BITARTRATE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 63629-1179 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; HYDROCODONE BITARTRATE 7.5 mg/1
- Imprint
- C 115
- Color
- white
- Shape
- CAPSULE
- Form
- TABLET
- Labeler
- Cranbury Pharmaceuticals, LLC
- Schedule
- CII
- NDC
- 27808-115 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; HYDROCODONE BITARTRATE 7.5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 63629-1181 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; HYDROCODONE BITARTRATE 7.5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 72162-1280 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; HYDROCODONE BITARTRATE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 63629-1183 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; HYDROCODONE BITARTRATE 5 mg/1
- Imprint
- M376
- Color
- white
- Shape
- OVAL
- Form
- TABLET
- Labeler
- SpecGx LLC
- Schedule
- CII
- NDC
- 0406-0376 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; HYDROCODONE BITARTRATE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 72162-1281 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; HYDROCODONE BITARTRATE 5 mg/1
- Imprint
- C 114
- Color
- white
- Shape
- CAPSULE
- Form
- TABLET
- Labeler
- Cranbury Pharmaceuticals, LLC
- Schedule
- CII
- NDC
- 27808-114 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; HYDROCODONE BITARTRATE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 63629-1184 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; HYDROCODONE BITARTRATE 10 mg/1
- Imprint
- C 116
- Color
- white
- Shape
- CAPSULE
- Form
- TABLET
- Labeler
- Cranbury Pharmaceuticals, LLC
- Schedule
- CII
- NDC
- 27808-116 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; HYDROCODONE BITARTRATE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Proficient Rx LP
- Schedule
- CII
- NDC
- 63187-375 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; HYDROCODONE BITARTRATE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 63629-8499 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; HYDROCODONE BITARTRATE 7.5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- NuCare Pharmaceuticals,Inc.
- Schedule
- CII
- NDC
- 68071-2645 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 300 mg/1; HYDROCODONE BITARTRATE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 72162-1287 ↗ · 2026-06-18
Dosage
Pending medical reviewer
